ELTX · Elicio Therapeutics, Inc.
$2.89
-0.06 (-2.03%)
At close · Jul 29
Market Cap
$56.30M
Shares
19.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.89
Open$3.00
Day$2.80–3.05
52W$2.66–16.00
Avg vol 30d3.1M
Short int1.9M · 9.8% float · 1.1d
Short vol50%
DataFeb 2021–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−68%
below
Price vs 50-day avg
−57%
below
RSI (14)
35
neutral
MACD trend
Positive
52-week position
2%
near low
Momentum
relative strength
1-month return
−26%
trailing
6-month return
−63%
trailing
YTD return
−64%
this year
Relative strength
−69%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
11 of 49 funds reported for Jun 30 · net +2.7K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.83% of float · ▲ +8.2% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
49 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
−92%
Y/Y
EPS growth
+39%
Y/Y
Free cash flow
$-37.0M
Balance sheet
$9.2M
net cash
Quant / Vol
risk profile
Volatility
143%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
19.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−68%
Bearish
Price vs 50-day avg
−57%
Bearish
RSI (14)
35
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
11 of 49 funds reported for Jun 30 · net +2.7K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.83% of float · ▲ +8.2% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
49 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $3 · 2%
52-wk high $16
vs 200-day avg -68%
vs 50-day avg -57%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELTX
this stock
Elicio Therapeutics, Inc.
|
$56.30M | -63.7% | +883.1% | — | 9.8% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +6.6% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELTX | -7.4% | -26.1% | -63.2% | -26.1% | -63.7% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -5.0% | -23.8% | -69.5% | -23.8% | -70.7% |
Key facts
CIK
1601485
CUSIP
28657F103
13F (30d)
11 filings
11 filers
Visit website
Investor relations